After a conference lacking the wow factor, biotech winners and losers emerge.
ApexOnco Front Page
Recent articles
16 September 2024
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
7 September 2024
The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.
6 September 2024
The depressed company could use Mylotarg as a stepping stone in AML.
5 September 2024
After Niagara the company faces three pivotal catalysts; none is a slam-dunk.
4 September 2024
The group eyes a broader use than Immunocore’s Kimmtrak.
2 September 2024
An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.
2 September 2024
A macrocycle-based therapy enters the clinic, as do projects targeting p53 interaction and IL-12.
Recent Quick take
- 30 July 2024
- 29 July 2024
- 26 July 2024
- 25 July 2024
- 25 July 2024
- 24 July 2024
- 24 July 2024
- 24 July 2024
- 23 July 2024
- 23 July 2024